(Q37584574)

21 August 2017

Molecular targeted therapy for biliary tract malignancy: defining the target (English)

1 reference

21 August 2017

Sarah B Fisher

1

1 reference

PMCID

3924630

21 August 2017

Kevin E Fisher

series ordinal

2

1 reference

PMCID

3924630

21 August 2017

Shishir K Maithel

series ordinal

3

1 reference

21 August 2017

1 December 2012

1 reference

Hepatobiliary surgery and nutrition

21 August 2017

1 reference

21 August 2017

1

1 reference

21 August 2017

1

1 reference

21 August 2017

53-54

1 reference

21 August 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Sorafenib in advanced hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Cetuximab for the treatment of colorectal cancer.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

23 August 2017

Biliary tract cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Biliary tract carcinomas: from chemotherapy to targeted therapy.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3924630

Biliary-tract cancer: improving therapy by adding molecularly targeted agents

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24570902

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3978/J.ISSN.2304-3881.2012.10.02

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

PMCID

3924630